In MAP2K1-mutant melanoma, there is one case report of a partial response to trametinib in a patient with stage IV-M1c melanoma, but resistance developed 3 months later and dose reduction was needed because of trametinib-induced skin-toxicity (Table 2) (19). Here, MAP2K1 is linked to melanoma.